40 patents currently held

2 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Sep 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Sep 2027

Next term end

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027 2028 2029 2030 2031 2032 2033 2034 2035 2036 203720382039204020412042 204320442045

notable patents all others Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Clinical Diagnostic System Including Instrument and Cartridge US 9,213,043

The most cited patent in this portfolio, cited by 50 later US patents, top 10% of utility patents granted in 2015 in our data. Protection runs to 2032.

Ends Nov 2032 · Medium confidence Also notable

Enveloped Virus Resistant to Complement Inactivation for the Treatment of Cancer US 11,274,141

Cited by 10 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2040.

Ends Jan 2040 · High confidence Also notable

Amine Compounds Having Anti-Inflammatory, Antifungal, Antiparasitic, and Anticancer Activity US 10,030,015

The largest patent family in this portfolio, 6 related applications, renewed at every maintenance window due so far. Protection runs to 2034.

Ends Jan 2034 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Feb 25, 2027
The maintenance fee for Compounds and Method for Reducing Uric Acid (US 9,115,072) comes due Feb 25, 2027. Unpaid by Aug 25, 2027, it lapses early.
2 fees due Mar 3 to 17, 2027 · next Mar 3
1 fee due Jun 15, 2027
The maintenance fee for Clinical Diagnostic System Including Instrument and Cartridge (US 9,213,043) comes due Jun 15, 2027. Unpaid by Dec 15, 2027, it lapses early.
2 fees due Jul 5 to 26, 2027 · next Jul 5
1 fee due Aug 23, 2027
The maintenance fee for Vectors Encoding Rod-Derived Cone Viability Factor (US 9,265,813) comes due Aug 23, 2027. Unpaid by Feb 23, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

1 of the patents on this record was granted since Aug 16, 2026
1 term has ended since Aug 16, 2026

What they patent

The 5 largest of its 28 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Complement Factor B Analogs and Their Uses	5 in force	to May 2032
Amine Compounds Having Anti-Inflammatory, Antifungal, Antiparasitic, and Anticancer Activity	3 in force	to Jan 2034
Clinical Diagnostic System Including Instrument and Cartridge	3 in force	to Jun 2033
Fusion Protein Between Short Form Rod-Derived Cone Viability Factor and a Hydrophilic Peptide	2 in force	to Oct 2037
Vectors Encoding Rod-Derived Cone Viability Factor	2 in force	to Oct 2032

Patents held now

Soonest term end first.

Patent	Title	Status	Expires	Confidence
US 7,915,429	Compounds for the Treatment of Metabolic Disorders In force Term ends Sep 10, 2027 · High confidence	In force	Term ends Sep 10, 2027	High confidence
US 8,022,249	Compounds for the Treatment of Metabolic Disorders In force (reinstated) Term ends Sep 30, 2027 · High confidence	In force (reinstated)	Term ends Sep 30, 2027	High confidence
US 7,935,689	Compounds for the Treatment of Metabolic Disorders In force (reinstated) Term ends Jan 22, 2028 · High confidence	In force (reinstated)	Term ends Jan 22, 2028	High confidence
US 8,044,243	Compounds for the Treatment of Metabolic Disorders In force (reinstated) Term ends Dec 30, 2028 · High confidence	In force (reinstated)	Term ends Dec 30, 2028	High confidence
US 9,115,072	Compounds and Method for Reducing Uric Acid In force (reinstated) Term ends Mar 13, 2029 · High confidence	In force (reinstated)	Term ends Mar 13, 2029	High confidence
US 8,178,675	Compounds for the Treatment of Metabolic Disorders In force Term ends Mar 14, 2029 · High confidence	In force	Term ends Mar 14, 2029	High confidence
US 8,889,724	Tetrazole Compounds for Reducing Uric Acid In force Term ends Apr 30, 2029 · High confidence	In force	Term ends Apr 30, 2029	High confidence
US 8,557,531	Detection of Circulating Endothelial Cells In force Term ends May 1, 2029 · High confidence	In force	Term ends May 1, 2029	High confidence
US 8,481,595	Compounds for the Treatment of Metabolic Disorders In force Term ends Oct 6, 2029 · High confidence	In force	Term ends Oct 6, 2029	High confidence
US 8,410,154	Tetrazole Compounds for Reducing Uric Acid In force Term ends Feb 12, 2030 · High confidence	In force	Term ends Feb 12, 2030	High confidence

10 of 40 patents shown.

Pro members see all 40.

Pro members: see all 40 patents

Also on record, not counted in the 40: 2 patents in force now held by others · 19 patents ended · 11 applications pending · 3 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Pharma Cinq, LLC